Published Date : Nov 21, 2016
ALBANY, NY, Nov 21, 2016: The 210-page report titled “HER2-Negative Breast Cancer - US Drug Forecast and Market Analysis To 2023” discusses the unmet needs in the HER2-negative breast cancer market in the U.S., the current landscape of treatment options, the commercial opportunities present, and the existing pipeline.
Breast cancer is known to be the most common cancer among women and the second most common type in the world. Although the five-year survival rate in breast cancer is comparatively high at around 90.0%, the report finds that this is subjective to the stage of the disease as well as its subtype. The main subtypes covered in this report are triple negative breast cancer (TNBC) and hormone receptor positive (HR+). The study also sheds light on the various therapeutic settings presently available for the treatment of breast cancer, especially in the U.S. These include first-, second-, third-, and fourth-line metastatic, adjuvant, and neoadjuvant.
The U.S. is a prime market for HER2-negative breast cancer and is likely to remain the dominant market through 2023, the end of the forecast period. This can be primarily attributed to the high incidence of HER2-negative breast cancer in the country. The influx of premium-priced products and a greater treatment rate in the adjuvant and neoadjuvant setting is also contributing toward the U.S. market for HER2-negative breast cancer.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/845847
The report finds that the prices of pipeline as well as existing therapies for HER2-negative breast cancer are higher than any other therapy. However, patients in the U.S. can afford these therapies because of the establishment of a private health insurance system, which ensures that even the latest and expensive drugs are made affordable with favorable reimbursement policies.
This study on the HER2-negative breast cancer market in the U.S. offers a detailed overview of the condition, discussing at length its etiology, epidemiology, diagnosis, symptoms, treatment options, and pathology. In-depth insight on the major drugs available in the country has been provided, in addition to detailed coverage on the product portfolio and their safety and efficacy. With the help of a SWOT reports, the strengths, weaknesses, opportunities, and threats of each product category have been identified and the sales forecast of the same have been provided for the period 2013 to 2023.
The drivers and restraints impacting the HER2-negative breast cancer market in the U.S., the various developments and events pertaining to the field, and an overview of the competitive landscape are also key aspects of this report. This enables clients to plan future strategies by identifying the most promising drugs. This, in turn, will allow them to stay ahead of the competition and gain a significant share in the U.S. HER2-negative breast cancer market.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org